Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina

About this update from Hemostemix Inc

[{"type":"text","content":"Hemostemix to Present Its Clinical Data of the Treatment of Severe AnginaCalgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces that Croom Lawrence will present Hemostemix's data on the treatment of Severe Angina Pectoris at the company's weekly webinar on Thursday, September 18, 2025.The presentation, entitled \"Treatment of Patients with Severe Angina Pectoris Using Intracoronarily Injected Autologous Blood-Borne Angiogenic Cell Precursors,\" compares the current standard of care—described as a \"slippery slope\" of limited options—to published results from a clinical pilot study of VesCell™ (ACP-01, Angiogenic Cell Precursors), reported in Circulation, Volume 114, Number Suppl_18.Study HighlightsThe clinical trial evaluated the safety and efficacy of intracoronary injection of autologous Angiogenic Cell Precursors (ACPs) in patients with chronic stable angina who had exhausted maximal drug therapy. Key findings included:Improved Exercise Tolerance: Six-minute walk distance increased from 333.65±26.56 meters at baseline to 414.95±28.54 meters at 3 months (P<0.001) and 413.25±33.17 meters at 6 months (P<0.001).Plain terms: Patients could walk about 80 more meters in six minutes after treatment—roughly the length of a football field—showing they had more stamina and less chest pain when walking a greater distance.Enhanced Exercise Capacity: Exercise capacity, measured in Metabolic Equivalents (METs)—a standard way of expressing how much energy the body uses during physical activity—rose from 5.62±0.52 at baseline to 6.73±0.64 at 3 months (P<0.004) and 7.09±0.79 at 6 months (P<0.04). (1 MET = sitting quietly, while higher numbers show ability to do harder activities.)Plain terms: Before treatment, most patients could only handle light to moderate activity. After treatment, they were able to do activities like climbing stairs or w...

More updates from Hemostemix Inc